$ZTS Platinium AM is bullish

Zoetis is the global leader in animal medicine. The company is the leading innovator in this industry, particularly in cat and dog treatments. Zoetis' underlying business is thriving, with profits up 14% over the past year and with the launch of some competing products unable to dent their momentum.
Their next leg of growth should come from an innovative treatment for Osteoarthritis in cats and dogs, a disease where there have been few effective treatment options.
This new drug has some rare side effects that the FDA is monitoring and so may require adjusted labelling. This drug has been available in the UK, EU and Switzerland for around two years and continues to sell well despite a similar label adjustment. However, Zoetis isn't cheap so investors are skittish when it comes to potential obstacles. We have confidence in this business and are keen to add to our position on pullbacks.